Inactive Instrument

Clovis Oncology, Inc.

Equities

CLVS.Q

US1894641000

Biotechnology & Medical Research

Clovis Oncology : Download PDF format download (opens in new window)

July 18, 2019 at 08:20 am EDT

NEWS RELEASE

Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1

7/18/2019

BOULDER, Colo.--(BUSINESSWIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2019 nancial results on Thursday, August 1, 2019, before the open of the U.S. nancial markets. Clovis' senior

management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company's results in greater detail.

The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.

Conference Call Details

Clovis will hold a conference call to discuss second quarter 2019 results on Thursday, August 1, at 8:30am ET. The conference call will be simultaneously webcast on the Company's web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: US participants 877.698.7048, International participants 647.689.5448, conference ID: 5192422.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at speciQc subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to beneGt from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional oWce locations in the U.S. and Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005086/en/

Clovis Investor Contacts:

Anna Sussman 303.625.5022

asussman@clovisoncology.com

Breanna Burkart 303.625.5023

bburkart@clovisoncology.com

Source: Clovis Oncology

Attachments

Original document
Permalink

Disclaimer

Clovis Oncology Inc. published this content on 18 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2019 12:19:02 UTC

Latest news about Clovis Oncology, Inc.

Clovis Oncology, Inc. Went Out of Business	23-07-10	CI
Revised Third Amened Joint Liquidation Plan Approved for Clovis Oncology, Inc.	23-06-16	CI
Third Amended Joint Liquidation Plan Filed by Clovis Oncology, Inc.	23-06-03	CI
Second Amended Joint Liquidation Plan Filed by Clovis Oncology, Inc.	23-05-31	CI
Zr pharma& GmbH completed the acquisition of certain assets and rights associated with Rubraca from Clovis Oncology, Inc. (OTCPK:CLVS.Q).	23-04-30	CI
US FDA panel backs restricted use of AstraZeneca's prostate cancer drug (April 28)	23-04-28	RE
First Motion for Exclusivity Period Extension Approved For Clovis Oncology, Inc.	23-04-28	CI
Combined Hearing for Disclosure Statement and Plan Approved On Interim Basis for Clovis Oncology, Inc.	23-04-21	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Clovis Oncology, Inc.	23-04-19	CI
Motion for Asset Sale Approved for Clovis Oncology, Inc.	23-04-12	CI
First Motion for Exclusivity Period Extension Filed by Clovis Oncology, Inc.	23-04-10	CI
Zr pharma& GmbH entered into an asset purchase agreement to acquire certain assets and rights associated with Rubraca from Clovis Oncology, Inc. (OTCPK:CLVS.Q) for approximately $140 million.	23-04-05	CI
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula	23-04-05	RE
Auction Result Filed for Clovis Oncology, Inc.	23-03-31	CI
North American Morning Briefing : Investor Mood -3-	23-03-29	DJ
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Joint Liquidation Plan and Disclosure Statement Filed by Clovis Oncology, Inc.	23-03-14	CI
Amended DIP Financing Approved for Clovis Oncology, Inc.	23-03-13	CI
North American Morning Briefing : Stock Futures -3-	23-03-08	DJ
Notice of Reschedule of Auction filed by Clovis Oncology, Inc.	23-03-08	CI
Notice for Auction Cancellation and Selection of Successful Bidder Filed by Clovis Oncology, Inc.	23-03-06	CI
North American Morning Briefing : Chinese -2-	23-03-01	DJ
North American Morning Briefing : Fed Minutes Eyed -2-	23-02-22	DJ
Final DIP Financing Approved for Clovis Oncology, Inc.	23-01-23	CI
Bidding Procedure Approved for Clovis Oncology, Inc.	23-01-23	CI

Chart Clovis Oncology, Inc.

Duration

Period

More charts

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR Î±/Î²) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.00%	103B
REGENERON PHARMACEUTICALS, INC.	+0.69%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.14%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.89%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.39%	13.86B
SAREPTA THERAPEUTICS, INC.	+35.26%	12.04B

Bio Therapeutic Drugs